Your browser doesn't support javascript.
loading
Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Artery Disease: Extended Follow-Up Outcomes of Multicenter Randomized Controlled BEST Trial.
Ahn, Jung-Min; Kang, Do-Yoon; Yun, Sung-Cheol; Ho Hur, Seung; Park, Hun-Jun; Tresukosol, Damras; Chol Kang, Woong; Moon Kwon, Hyuck; Rha, Seung-Woon; Lim, Do-Sun; Jeong, Myung-Ho; Lee, Bong-Ki; Huang, He; Hyo Lim, Young; Ho Bae, Jang; Ok Kim, Byung; Kiam Ong, Tiong; Gyun Ahn, Sung; Chung, Cheol-Hyun; Park, Duk-Woo; Park, Seung-Jung.
Afiliación
  • Ahn JM; Heart Institute (J.-M.A., D.-Y.K., C.-H.C., D.-W.P., S.-J.P.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Kang DY; Heart Institute (J.-M.A., D.-Y.K., C.-H.C., D.-W.P., S.-J.P.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Yun SC; Division of Biostatistics, Center for Medical Research and Information (S.-C.Y.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Ho Hur S; Keimyung University Dongsan Medical Center, Daegu, South Korea (S.H.H.).
  • Park HJ; Catholic University of Korea, Seoul St. Mary's Hospital (H.-J.P.).
  • Tresukosol D; Siriraj Hospital, Bangkok, Thailand (D.T.).
  • Chol Kang W; Gachon University Gil Hospital, Incheon, South Korea (W.C.K.).
  • Moon Kwon H; Gangnam Severance Hospital, Seoul, South Korea (H.M.K.).
  • Rha SW; Korea University Guro Hospital, Seoul (S.-W.R.).
  • Lim DS; Korea University Anam Hospital, Seoul (D.-S.L.).
  • Jeong MH; Chonnam National University Hospital, Gwangju, South Korea (M.-H.J.).
  • Lee BK; Kangwon National University Hospital, Chuncheon, South Korea (B.-K.L.).
  • Huang H; Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China (H.H.).
  • Hyo Lim Y; Hanyang University Hospital, Seoul, South Korea (Y.H.L.).
  • Ho Bae J; Konyang University Hospital, Daejeon, South Korea (J.H.B.).
  • Ok Kim B; Inje University Sanggye Paik Hospital, Seoul, South Korea (B.O.K.).
  • Kiam Ong T; Sarawak General Hospital, Kuching, Sarawak, Malaysia (T.K.O.).
  • Gyun Ahn S; Yonsei University Wonju Severance Christian Hospital, Wonju, South Korea (S.G.A.).
  • Chung CH; Heart Institute (J.-M.A., D.-Y.K., C.-H.C., D.-W.P., S.-J.P.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Park DW; Heart Institute (J.-M.A., D.-Y.K., C.-H.C., D.-W.P., S.-J.P.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Park SJ; Heart Institute (J.-M.A., D.-Y.K., C.-H.C., D.-W.P., S.-J.P.), Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Circulation ; 146(21): 1581-1590, 2022 11 22.
Article en En | MEDLINE | ID: mdl-36121700
ABSTRACT

BACKGROUND:

Long-term comparative outcomes after percutaneous coronary intervention (PCI) with everolimus-eluting stents and coronary artery bypass grafting (CABG) are limited in patients with multivessel coronary artery disease.

METHODS:

This prospective, multicenter, randomized controlled trial was conducted in 27 international heart centers and was designed to randomly assign 1776 patients with angiographic multivessel coronary artery disease to receive PCI with everolimus-eluting stents or CABG. After inclusion of 880 patients (438 in the PCI group and 442 in the CABG group) between July 2008 and September 2013, the study was terminated early because of slow enrollment. The primary end point was the composite of death from any cause, myocardial infarction, or target vessel revascularization.

RESULTS:

During a median follow-up of 11.8 years (interquartile range, 10.6-12.5 years; maximum, 13.7 years), the primary end point occurred in 151 patients (34.5%) in the PCI group and 134 patients (30.3%) in the CABG group (hazard ratio [HR], 1.18 [95% CI, 0.88-1.56]; P=0.26). No significant differences were seen in the occurrence of a safety composite of death, myocardial infarction, or stroke between groups (28.8% and 27.1%; HR, 1.07 [95% CI, 0.75-1.53]; P=0.70), as well as the occurrence of death from any cause (20.5% and 19.9%; HR, 1.04 [95% CI, 0.65-1.67]; P=0.86). However, spontaneous myocardial infarction (7.1% and 3.8%; HR, 1.86 [95% CI, 1.06-3.27]; P=0.031) and any repeat revascularization (22.6% and 12.7%; HR, 1.92 [95% CI, 1.58-2.32]; P<0.001) were more frequent after PCI than after CABG.

CONCLUSIONS:

In patients with multivessel coronary artery disease, there were no significant differences between PCI and CABG in the incidence of major adverse cardiac events, the safety composite end point, and all-cause mortality during the extended follow-up. REGISTRATION URL https//www. CLINICALTRIALS gov; Unique identifiers NCT05125367 and NCT00997828.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Infarto del Miocardio Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Circulation Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedad de la Arteria Coronaria / Stents Liberadores de Fármacos / Intervención Coronaria Percutánea / Infarto del Miocardio Tipo de estudio: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Circulation Año: 2022 Tipo del documento: Article País de afiliación: Corea del Sur